EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseVergleichsstudieOpen Access · CC BY-NC 4.0

Comparative Efficacy and Safety of Systemic Immunomodulatory Therapies for Non‐Infectious Uveitis: A Systematic Review With Pairwise and Network Meta‐Analyses

Kai-Yang Chen iD, Hoi-Chun Chan, Chi-Ming Chan iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026-11 · 46 (11)

DOI: 10.1002/phar.70184 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 13.10.2026. Verfasst von Kai-Yang Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, Chang Gung Memorial Hospital (Linkou Branch), Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Uveitis, Immunosuppressive Agents, Immunomodulating Agents. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Science and Technology Council Taiwan, Cardinal Tien Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Non‐infectious uveitis (NIU) is a chronic immune‐mediated ocular inflammatory disease that may cause irreversible visual impairment. The comparative efficacy and safety of systemic immunomodulatory therapies, including conventional agents and biologics, remain incompletely defined. This systematic review and network meta‐analysis evaluated systemic immunosuppressive therapies for NIU.

Methods

PubMed/MEDLINE, Cochrane CENTRAL, Scopus and Web of Science Core Collection were searched from inception to May 2, 2026. Randomized controlled trials and prospective comparative cohort studies evaluating systemic immunomodulatory or biologic therapies for NIU were included. The primary efficacy outcome was treatment failure. Safety outcomes included mortality, urinary tract infection, upper respiratory tract infection, injection‐site reactions, ocular hypertension, macular edema, and headache. Random‐effects pairwise meta‐analysis and frequentist network meta‐analysis were performed using risk ratios (RRs) with 95% confidence intervals (CIs).

Results

Seven studies including 992 participants were included; six were randomized controlled trials and one was a prospective cohort. In the pairwise meta‐analysis, adalimumab significantly reduced treatment failure compared with placebo (RR, 0.67; 95% CI, 0.58–0.78; p < 0.0001; I² = 28.1%). The mortality estimate was inconclusive (RR, 3.80; 95% CI, 0.42–34.15), with three deaths in the adalimumab groups and none in the placebo groups. Adalimumab was associated with a higher risk of injection‐site reactions than placebo (RR, 2.67; 95% CI, 1.73–4.12). Network meta‐analysis showed no significant differences for most safety outcomes, including upper respiratory tract infection, ocular hypertension, macular edema, and headache. Infliximab showed an imprecise urinary tract infection signal versus placebo (RR, 40.98; 95% CI, 1.82–922.17), based on sparse events and one nonrandomized comparison.

Conclusion

Adalimumab provides the most consistent evidence for reducing treatment failure in NIU. Comparative safety estimates, particularly for infliximab, remain uncertain and hypothesis‐generating. Larger, long‐term, head‐to‐head trials are required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UveitisImmunosuppressive AgentsImmunomodulating AgentsHumansAdalimumabRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

adalimumabimmunosuppressant therapyinfliximabnetwork meta‐analysisnon‐infectious uveitis

Substanzen

Immunosuppressive AgentsAdalimumabImmunomodulating Agents

Autor:innen und Institutionen

  • Department of General Medicine, Chang Gung Memorial Hospital (Linkou Branch), Taoyuan, Taiwan.
  • School of Pharmacy, China Medical University, Taichung, Taiwan.
  • Department of Ophthalmology, Cardinal Tien Hospital, New Taipei City, Taiwan.
  • School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.

ORCID-Profile: Kai-Yang Chen, Chi-Ming Chan

Förderung

  • National Science and Technology Council Taiwan
  • Cardinal Tien Hospital

Zitieren

APA

Chen, K. Y., Chan, H. C., & Chan, C. M. (2026). Comparative Efficacy and Safety of Systemic Immunomodulatory Therapies for Non‐Infectious Uveitis: A Systematic Review With Pairwise and Network Meta‐Analyses. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 46(11). https://doi.org/10.1002/phar.70184

Vancouver

Chen KY, Chan HC, Chan CM. Comparative Efficacy and Safety of Systemic Immunomodulatory Therapies for Non‐Infectious Uveitis: A Systematic Review With Pairwise and Network Meta‐Analyses. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026;46(11). doi:10.1002/phar.70184

BibTeX
@article{Chen2026,
  author = {Chen, Kai-Yang and Chan, Hoi-Chun and Chan, Chi-Ming},
  title = {Comparative Efficacy and Safety of Systemic Immunomodulatory Therapies for Non‐Infectious Uveitis: A Systematic Review With Pairwise and Network Meta‐Analyses},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2026},
  volume = {46},
  number = {11},
  doi = {10.1002/phar.70184}
}
Kostenlos starten →